platinum has been researched along with paclitaxel in 147 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (10.20) | 18.2507 |
| 2000's | 33 (22.45) | 29.6817 |
| 2010's | 53 (36.05) | 24.3611 |
| 2020's | 46 (31.29) | 2.80 |
| Authors | Studies |
|---|---|
| Plaxe, SC | 1 |
| Groshen, S; Jeffers, S; Morris, M; Muderspach, L; Muggia, F; Roman, L; Russell, C; Uziely, B | 1 |
| Bonneterre, J; Dauplat, J; Fumoleau, P; Guastalla, JP; Kerbrat, P; Lhommé, C; Namer, M; Oberling, F; Pouillart, P; Tubiana, N | 1 |
| Eisenhauer, E; Swenerton, K; ten Bokkel Huinink, WW | 1 |
| Jones, WB; Lewis, JL; Schneider, J; Shapiro, F | 1 |
| Francis, PA; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC; Walcher, V | 1 |
| Kucera, E; Mayerhofer, K; Reinthaller, A; Sevelda, P; Speiser, P; Zeisler, H | 1 |
| Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W | 1 |
| Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG | 1 |
| Sabbatini, P; Spriggs, D | 1 |
| Belinson, J; Ernst, S; Homesley, H; Kennedy, A; Lichtman, SM; Markman, M; Omura, G; Webster, K | 1 |
| Amoroso, M; Bolis, G; Parazzini, F; Pirletti, E; Polatti, A; Rabaiotti, E; Reina, S; Scarfone, G; Villa, A | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Armand, JP; Cunningham, D; Kohne, CH; Misset, JL; van Cutsem, E | 1 |
| Kaye, SB | 1 |
| Agostino, M; Bartus, RT; Emerich, DF; Marsh, J; Perkins, A; Snodgrass, P | 1 |
| Comerci, JT; Edwards, RP; Kanbour-Shakir, A; Kelley, JL; Kunschner, AJ; Price, FV; Sit, AS | 1 |
| Fujiwara, K; Fujiwara, M; Ishikawa, H; Kohno, I; Suzuki, S; Tanaka, Y; Yamauchi, H | 1 |
| Stefanov, VE; Tulub, AA | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Kehoe, S; Selman, T | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Long, HJ; Peethambaram, PP | 1 |
| Aghajanian, C; Dizon, DS; Hensley, ML; Hummer, A; Poynor, EA; Sabbatini, P; Spriggs, DR; Venkatraman, E | 1 |
| Balcerzak, S; Bender, J; Brooks, R; Chan, KK; D'Ambrosio, S; Gibson-D'Ambrosio, R; Grever, M; Kraut, E; Liu, J; Stanley, H | 1 |
| Baekelandt, M; Kaern, J; Tropé, CG | 1 |
| Cosio, S; Gadducci, A; Genazzani, AR; Muraca, S | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Markman, M | 2 |
| Greco, FA | 1 |
| Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A | 1 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| Fujii, K; Kikuchi, Y; Kita, T; Okamoto, S; Sasaki, N; Takano, M | 1 |
| Sugiyama, T | 1 |
| Bak, JY; Bang, YJ; Choi, IS; Heo, DS; Kim, DW; Kim, JH; Kim, NK; Kim, SI; Kim, TY; Kim, YT; Kim, YW; Kwon, JH; Oh, DY; Park, CI; Park, SR; Sung, SW; You, CK | 1 |
| Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J | 1 |
| Chang, HM; Choi, SJ; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, YH; Ryu, BY | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Hiyama, E; Hiyama, K; Kigawa, J; Komatsu, M; Kudo, Y; Nagai, N; Nishiyama, M; Ohtaki, M; Ohwada, M; Otani, K; Suzuki, M; Tanimoto, K; Yunokawa, M | 1 |
| Alvarez, RD; Barnes, MN; Huh, WK; Kilgore, LC; Leath, CA; Partridge, EE; Rocconi, RP; Straughn, JM | 1 |
| Ferrandina, G; Martinelli, E; Paglia, A; Ranelletti, FO; Scambia, G; Zannoni, GF | 1 |
| Ahn, JS; Ahn, YC; Choi, YS; Kim, H; Kim, J; Kim, K; Park, BB; Park, JO; Park, K; Shim, YM | 1 |
| He, SR; Wei, FH; Yang, L; Zhang, Y; Zhao, XD | 1 |
| Cannon, M; Cmelak, AJ; Forastiere, AA; Gillison, M; Goldwasser, MA; Li, S; Murphy, B; Pinto, H; Rosenthal, DI | 1 |
| Jett, JR; Keith, RL; Kesler, KA; Schild, SE | 1 |
| Basuyau, JP; Dalifard, I; Eche, N; Hacene, K; Pichon, MF; Riedinger, JM | 1 |
| Allan, S; Bajdik, C; Chia, S; Gelmon, KA; Hassell, P; Hayes, MM; Norris, B; O'Reilly, SE; Shenkier, TN; Speers, C; Yerushalmi, R | 1 |
| Ballardini, M; Carpi, A; Conte, P; Favalli, G; Gadducci, A; Katsaros, D; Nanni, O; Panici, PB; Pecorelli, S; Scambia, G | 1 |
| Allocco, DJ; Britt, A; Cannon, LA; Dawkins, KD; Heil, JE; Kereiakes, DJ; Nersesov, A; Wehrenberg, S | 1 |
| Chun, KC; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Nam, JH | 1 |
| Ball, MW; Bertolet, B; Cannon, LA; Dauber, IM; Dawkins, KD; Feldman, RL; Foster, MC; Kabour, A; Kereiakes, DJ; Magorien, R; Popma, JJ; Rabinowitz, AC; Underwood, P; Wang, JC; Whitbourn, R | 1 |
| Alexandre, J; Cottu, P; Falandry, C; Floquet, A; Lebrun, D; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Weber, B | 1 |
| Aavall-Lundqvist, E; Brown, C; du Bois, A; Ferrero, A; Gebski, V; Heywood, M; Jackisch, C; Joly, F; Kristensen, G; Le Fur, N; Lortholary, A; Pignata, S; Pujade-Lauraine, E; Sehouli, J; Vasey, PA; Vergote, I; Volgger, B; Wagner, U | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Berchuck, A; Havrilesky, LJ; Higgins, RV; Kohler, MF; Myers, ER; Nycum, LR; Pokrzywinski, R; Revicki, D; Secord, AA | 1 |
| Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M | 1 |
| Aghajanian, CA; Berlin, S; Hensley, ML; Iasonos, A; Jia, X; Kravetz, S; Pereira, L; Sabbatini, P; Tew, W; Whalen, C; Zarwan, C | 1 |
| Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S | 1 |
| Bonaventura, T; Brown, C; Fossati, R; Gebski, V; Heywood, M; Kaern, J; Largillier, R; Lauraine, EP; Marth, C; Piccirillo, MC; Vergote, I; Wagner, U | 1 |
| Sillerud, LO; Taylor, RM | 1 |
| Alici, S; Berk, V; Camcı, C; Coskun, U; Degerli, H; Gumus, M; Kaya, AO; Kefeli, U; Oner, MK; Ozdemir, NY; Ozkan, M; Ozturk, C; Sevinc, A; Unal, OU; Yilmaz, AU | 1 |
| Baumann, K; Belau, A; Bentley, J; Berton-Rigaud, D; Brown, C; Canzler, U; Friedlander, M; Gebski, V; Kristensen, G; Kurzeder, C; Ledermann, JA; Lee, CK; Lord, SJ; Nankivell, M; Parma, G; Pfisterer, J; Pisano, C; Plante, M; Pujade-Lauraine, E; Schauer, C; Simes, RJ; Skeie-Jensen, T; Swart, AM; Vergote, I | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Bodnar, L; Grala, B; Kozlowski, W; Smoter, M; Stec, R; Szczylik, C; Zieniuk, K | 1 |
| Ding, ZY; Liu, YM; Wang, C; Zhou, L | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V | 1 |
| Bai, Y; Chu, YP; Gong, JF; Li, J; Li, Y; Shen, L; Zhang, XT | 1 |
| Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y | 1 |
| Banerjee, S; Clamp, A; Dawson-Athey, L; Earl, H; Feeney, A; Hall, G; Hall, M; James, L; Kaye, SB; Khan, I; Kristeleit, R; Lawrence, C; Ledermann, JA; McNeish, IA; Persic, M; Raja, F; Webber, L | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T | 1 |
| Allocco, DJ; Calabria, P; Capodanno, D; Crowley, JJ; Dawkins, KD; Erglis, A; Gilbert, TJ; Horváth, IG; Menown, IB; Moreno, R; Tamburino, C | 1 |
| Jansaka, N; Suprasert, P | 1 |
| Allocco, DJ; Ball, M; Bertolet, B; Cannon, LA; Dauber, I; Dawkins, KD; Foster, M; Kereiakes, DJ; Nersesov, AY; Underwood, PL | 1 |
| Hiura, K; Iwaki-Egawa, S; Komori, H; Shiraishi, A; Suzuki, C; Takamura, K; Watanabe, Y; Yamamoto, M | 1 |
| Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S | 1 |
| Ito, Y; Kikuchi, E; Kosaka, T; Miyajima, A; Mizuno, R; Oya, M; Shinojima, T; Suzuki, E; Tanaka, N; Umezawa, K | 1 |
| Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y | 1 |
| Davies, L; García-Martínez, E; Gebski, V; Gladieff, L; Hilpert, F; Khoon Lee, C; Kristensen, G; Los, M; Mahner, S; Pujade-Lauraine, E; Savarese, A; Sehouli, J; Trillsch, F; Vuylsteke, P; Zagouri, F | 1 |
| Lin, W; Sun, T; Xie, Z; Zhang, W | 1 |
| Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
| Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S | 1 |
| Baratelli, C; Chau, I; Cunningham, D; Kalaitzaki, E; Morano, F; Rao, S; Sclafani, F; Starling, N; Watkins, D | 1 |
| Amato, LB; Bucci, C; Dusi, S; Gasparre, G; Girolimetti, G; Guerra, F; Iommarini, L; Kurelac, I; Leone, G; Maffia, M; Perrone, AM; Porcelli, AM; Tiranti, V; Vergara, D; Vidone, M | 1 |
| Gao, H; He, K; Li, X; Liu, X; Qin, H; Tang, C; Wang, H; Wang, W; Xu, B; Yang, S; Zhao, G | 1 |
| Broggini, M; Damia, G; Guffanti, F; Ricci, F | 1 |
| Araki, T; Azimi, Z; Imai, S; Kaneko, S; Koyanagi, M; Matsubara, K; Matsumoto, M; Nakagawa, S; Nakagawa, T; Nakazato, Y; Ogihara, T; Omura, T; Wakatsuki, S; Yonezawa, A | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Hashimoto, H; Kontani, K; Mimura, M; Miyatake, T; Nagamatsu, M; Nishikawa, A; Takeda, M; Yokoi, T | 1 |
| Wang, Y; Xu, F; Xu, H; Ying, J; Zhu, W | 1 |
| Robson, M | 1 |
| Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E | 1 |
| Cannon, LA; Dawkins, KD; Grady, TP; Hill, R; Kimmelstiel, CD; Myers, PR; Underwood, P; White, A | 1 |
| de Castria, TB; Fujiki, FK; Hoff, PMG; Takeda, FR; Victor, CR | 1 |
| Al-Chamali, H; Bird, T; Cox, C; Dorey, N; Gomberg, S; Goody, R; Hingorani, M; Hurt, C; Macgregor, U; Mukherjee, S; Owens, R; Pan, S; Parikh, S; Prince, S; Radhakrishna, G | 1 |
| Bradford, DS; Crane, J; Deal, AM; Irvin, W; Lee, C; Morgensztern, D; Muss, HB; Pecot, C; Pennell, N; Socinski, M; Stevenson, JP; Stinchcombe, T; Villaruz, LC; Weiss, JM; West, HJ | 1 |
| Biggs, S; Cayre, OJ; Dupont, H; Hitchcock, J; Hondow, N; Hughes, TA; White, AL | 1 |
| Gao, W; Huang, Y; Li, T; Li, X; Mao, C; Shen, J; Wan, M; Wang, Q; Zhou, M | 1 |
| Fang, T; Shen, Q; Wu, G; Xu, Y; Yang, J; Yang, Y; Zhang, J; Zuo, T | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Mahmoud, H | 1 |
| Alessi, A; Bandini, M; Briganti, A; Calareso, G; Colecchia, M; Farè, E; Gallina, A; Giannatempo, P; Madison, R; Marandino, L; Montorsi, F; Necchi, A; Raggi, D; Ross, JS | 1 |
| Funada, S; Luo, Y; Yoshioka, T | 1 |
| Ding, K; Parulekar, WR; Sridhar, SS | 1 |
| Brown, R; Chiu, DS; Choi, H; Hoppe, MM; Huntsman, DG; Jaynes, P; Jeyasekharan, AD; Karnezis, A; Kaye, SB; Leung, S; Lie, S; Lim, DGZ; Lim, S; P S Yeong, J; Pang, BNK; Patel, NR; Pitt, JJ; Sato, K; Scott, CL; Sedukhina, AS; Tan, DSP; Tan, TZ; Topp, MD; Upadhyayula, SS; Wardyn, JD | 1 |
| Huang, J; Li, L; Liu, H; Lv, Y; Wang, F; Yin, F; Zhao, C; Zheng, Q | 1 |
| Fujiwara, H; Fujiwara, K; Kanuma, T; Nakamura, K; Nakamura, Y; Sakurai, M; Satoh, T; Suzuki, M; Takahashi, S; Takei, Y | 1 |
| Apaijai, N; Charoenkwan, K; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Khunamornpong, S; Kingnate, C; Kumfu, S | 1 |
| Miao, J; Wang, M; Wu, Y; Yin, Z | 1 |
| Kim, HS; Lee, M; Lee, N; Lee, S; Paik, H; Park, SJ; Yim, GW | 1 |
| Fujimoto, N; Harada, M; Inatomi, H; Minato, A; Onishi, R; Terado, M; Tomisaki, I | 1 |
| Yuasa, T | 1 |
| Adorni, M; Bazzurini, L; Buda, A; Grassi, T; Landoni, F; Lissoni, AA; Negri, S; Vecchione, F | 1 |
| De, A; Deo, AN; Dhadve, AC; Ray, P; Rekhi, B; Thorat, R | 1 |
| Cadoo, KA; Chambers, SK; Chen, LM; Chmielecki, J; Cragun, JM; Geenen, JJJ; Ghamande, SA; Hamilton, EP; Jones, SF; Konecny, GE; Kumar, S; Lai, Z; Moore, KN; Mugundu, GM; Oza, AM; Plaxe, SC; Rodrigo Imedio, E; Spigel, DR; Spitz, DL; Troso-Sandoval, TA | 1 |
| Chang, WH; Chen, YJ; Huang, HY; Lee, NR; Lin, SC; Su, MH; Wang, PH; Wu, HH | 1 |
| Dong, X; Jia, Y; Song, X; Song, Y; Wang, W; Yi, Y; Zhang, J | 1 |
| Cai, L; Chen, C; Deng, H; Li, S; Lin, X; Liu, M; Qin, Y; Qiu, G; Xie, X; Xie, Z; Yang, Y; Zhou, C | 1 |
| Chang, CH; Chang, YL; Chen, JS; Hsu, FM; Huang, YL; Lee, JM; Lin, CC; Ma, WL; Yang, JC | 1 |
| Benjamin, L; Corr, BR; Culm-Merdek, K; Fu, S; Hamilton, EP; Mockbee, C; Moore, KN; Naumann, RW; Rosengarten, RD; Stagg, R; Wenham, RM; Youssoufian, H | 1 |
| Abu-Hejleh, T; Allen, BG; Bellizzi, AM; Bodeker, KL; Bossler, AD; Buatti, JM; Buettner, GR; Byrne, MM; Cullen, JJ; Fath, MA; Furqan, M; Hartwig, SM; Henrich, JB; Houtman, JC; Ivanovic, M; Mani, H; Monga, V; Mott, SL; Petronek, M; Pulliam, CF; Smith, BJ; Spitz, DR; Stephens, LM; Varga, SM; Wagner, BA; Zeitler, W; Zhang, J | 1 |
| Duenas-Gonzalez, A | 1 |
| Ma, J; Zhang, S | 1 |
| He, ZY; Li, DC; Li, HY; Li, SJ; Liang, ZZ; Yan, J | 1 |
| Berger, J; Boisen, M; Buckanovich, R; Coffman, LG; Courtney-Brooks, M; Edwards, RP; Frisbie, LG; Griffith, K; Lesnock, J; Liu, T; Mahdi, H; McLean, K; Normolle, D; Olawaiye, A; Orellana, TJ; Sukumvanich, P; Taylor, SE; Uppal, S | 1 |
| Gibson, MK; Weidenbaum, C | 1 |
| Arenare, L; Artioli, G; Baldassarre, G; Beltrame, L; Califano, D; Campanini, N; Capoluongo, ED; Cecere, SC; Chiodini, P; Cinieri, S; Colombo, N; D'Incalci, M; De Cecio, R; Llop-Guevara, A; Lorusso, D; Marchini, S; Mezzanzanica, D; Musolino, A; Nardelli, C; Normanno, N; Pellegrino, B; Perrone, F; Pignata, S; Pisano, C; Roma, C; Russo, D; Scaglione, GL; Scambia, G; Sergi, A; Serra, V; Setaro, M; Spina, A; Tasca, G | 1 |
| Enzinger, PC; Guo, H; Joo, S; Meng, Y; Qu, T; Zhang, S; Zhong, Y | 1 |
| Ikeda, M; Iwamura, M; Katsumata, H; Koguchi, D; Matsumoto, K; Nakamura, M; Sato, Y; Shimizu, Y; Shiono, Y | 1 |
| Frountzas, M; Haidopoulos, D; Liatsou, E; Liontos, M; Papapanagiotou, A; Pergialiotis, V; Rodolakis, A; Thomakos, N | 1 |
| Dong, Q; Du, F; Gao, L; Huo, X; Li, Z; Liu, Z; Ren, D; Shen, G; Wang, M; Xie, Q; Xin, Y; Zhao, F; Zhao, J; Zhao, Y | 1 |
| Hou, H; Jiang, M; Li, T; Sun, D; Wang, Y; Zhang, C; Zhang, X; Zhou, N; Zhu, J | 1 |
| Chen, Y; Han, R; Hao, Y; He, X; Liu, Q; Liu, T; Qian, Z; Yang, C; Yang, Y | 1 |
| Frances, N; Geiger, K; Hartung, N; Henrich, A; Holdenrieder, S; Huisinga, W; Joerger, M; Kloft, C; Nassar, YM; Ojara, FW | 1 |
| Han, Z; Hong, Z; Li, S; Qin, Y; Wang, L; Wang, X; Zhu, D | 1 |
| Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E | 1 |
| Belleville, E; Brucker, SY; Erber, R; Fasching, PA; Fehm, TN; Häberle, L; Hack, CC; Hartkopf, AD; Hartmann, A; Hein, A; Janni, W; Kolberg, HC; Rübner, M; Theuser, AK; Uhrig, S; Untch, M | 1 |
| Hirata, T; Kawai, Y; Kishigami, Y; Kondo, E; Kotaka, S; Nagao, K; Okamoto, K; Suzuki, S; Yamawaki, T | 1 |
| Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Nishio, M; Ohe, Y; Sugawara, S; Takahashi, S; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
| Aiba, T; Domeki, Y; Kawana, S; Kawashima, Y; Kimura, Y; Nakamura, A; Sugawara, S; Sugisaka, J; Toi, Y; Yamanda, S | 1 |
19 review(s) available for platinum and paclitaxel
| Article | Year |
|---|---|
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 1997 |
Salvage therapy for ovarian cancer.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Forecasting; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Salvage Therapy; Treatment Failure | 1998 |
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Quinazolines; Taxoids; Thiophenes; Topoisomerase I Inhibitors | 1999 |
Progress in the treatment of ovarian cancer. Scottish Gynaecological Cancer Trials Group.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Second-line and subsequent therapy for ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Genetic Therapy; Hematopoietic Stem Cell Mobilization; Humans; Immunotherapy; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Treatment Outcome | 2002 |
Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Molecular Biology; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2002 |
Consolidation/maintenance chemotherapy for ovarian cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Women's Health | 2003 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
The Evolving Arena of Ovarian Cancer Maintenance Therapy.
Topics: Bevacizumab; Drug Therapy; Female; Humans; Medical Oncology; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies | 2020 |
The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lung Neoplasms; Monte Carlo Method; Neoplasm Staging; Paclitaxel; Platinum; Survival Analysis | 2021 |
The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: analysis of three cases and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Fetus; Humans; Infant; Infant, Newborn; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Platinum; Pregnancy | 2022 |
Combinational therapies for the treatment of advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Female; Humans; Paclitaxel; Platinum; Uterine Cervical Neoplasms | 2023 |
Approach to Localized Squamous Cell Cancer of the Esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Platinum; Quality of Life | 2022 |
Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum-Paclitaxel Chemotherapy: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Proportional Hazards Models | 2023 |
Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Topics: Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Female; Humans; Myalgia; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Platinum; Prognosis; Triple Negative Breast Neoplasms | 2023 |
43 trial(s) available for platinum and paclitaxel
| Article | Year |
|---|---|
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications.
Topics: Adult; Aged; Bacterial Infections; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Premedication; Risk Factors; Survival Analysis | 1994 |
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
Topics: Adult; Aged; Chlorpheniramine; Cimetidine; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Prednisolone; Premedication; Prospective Studies; Salvage Therapy; Stereoisomerism | 1994 |
Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Premedication | 1993 |
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 1996 |
Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Platinum | 1998 |
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Failure | 1999 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; DNA Adducts; Dose-Response Relationship, Drug; Drug Interactions; Head and Neck Neoplasms; Humans; Leukocytes; Mass Spectrometry; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Reproducibility of Results | 2002 |
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.
Topics: Adult; Aged; Analysis of Variance; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Probability; Remission Induction; Risk Assessment; Survival Rate; Treatment Outcome | 2002 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Stomach Neoplasms | 2005 |
Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deglutition Disorders; Female; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Pharyngectomy; Platinum; Radiotherapy, Adjuvant; Recovery of Function; Salvage Therapy; Speech Disorders; Taxoids; Treatment Outcome | 2007 |
A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Platinum; Treatment Outcome | 2009 |
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epithelial Cells; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Proportional Hazards Models; Treatment Outcome; Young Adult | 2009 |
A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program.
Topics: Angioplasty, Balloon, Coronary; Australia; Bayes Theorem; Cardiovascular Agents; Chromium Alloys; Coronary Angiography; Coronary Artery Disease; Data Interpretation, Statistical; Drug-Eluting Stents; Humans; New Zealand; Paclitaxel; Platelet Aggregation Inhibitors; Platinum; Prospective Studies; Prosthesis Design; Research Design; Severity of Illness Index; Singapore; Single-Blind Method; Stents; Time Factors; Treatment Outcome; United States | 2010 |
Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXU
Topics: Aged; Chromium; Chromium Alloys; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Platinum; Prospective Studies; Single-Blind Method; Treatment Outcome | 2010 |
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Recurrence | 2010 |
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Furans; Humans; Ketones; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Retreatment; Tubulin Modulators | 2012 |
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Platinum; Polyethylene Glycols; Recurrence; Treatment Outcome | 2012 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Platinum; Pyrimidines; Stomach Neoplasms | 2013 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Platinum; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quinazolines; Retroperitoneal Neoplasms | 2014 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Bayes Theorem; Chromium; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Patient Selection; Platinum; Prospective Studies; Prosthesis Design; Prosthesis Failure; Risk Assessment; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Survival Rate; Taxus; Time Factors; Treatment Outcome; United States | 2015 |
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome | 2015 |
Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Safety | 2015 |
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Treatment Outcome | 2016 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate | 2017 |
[Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peptides; Platinum; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Young Adult | 2017 |
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arachis; Humans; Paclitaxel; Platinum; Salvage Therapy | 2020 |
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Platinum; Quality of Life; Randomized Controlled Trials as Topic; Selenium | 2021 |
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; RNA; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2022 |
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Paclitaxel; Platinum | 2022 |
A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms | 2022 |
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Purines | 2022 |
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Topics: Bevacizumab; Carboplatin; Female; Homologous Recombination; Humans; Mangifera; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerases | 2022 |
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Platinum | 2023 |
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum; Prospective Studies; Quality of Life; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis | 2023 |
85 other study(ies) available for platinum and paclitaxel
| Article | Year |
|---|---|
Ovarian cancer.
Topics: Female; Humans; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate; United States | 1994 |
Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Frontal Lobe; Humans; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine | 1996 |
Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Rate | 1997 |
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome | 1998 |
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.
Topics: Adenocarcinoma; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Platinum; Remission Induction | 1999 |
Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival.
Topics: Animals; Antineoplastic Agents; Bradykinin; Brain Neoplasms; Carboplatin; Glioma; Infusions, Intravenous; Male; Paclitaxel; Platinum; Rats; Rats, Inbred F344 | 2000 |
Chemotherapy for malignant mixed Müllerian tumors of the ovary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin.
Topics: Age Factors; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Carboplatin; Cyclophosphamide; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platelet Count; Platinum; Prospective Studies; Thrombocytopenia | 2001 |
Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes.
Topics: Animals; Antineoplastic Agents; Cattle; Cisplatin; Guanosine Triphosphate; Hydrogen Bonding; Hydrolysis; Kinetics; Magnetic Resonance Spectroscopy; Male; Microscopy, Electron; Microtubules; Paclitaxel; Platinum; Tubulin | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Tumour markers in ovarian cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Treatment Outcome | 2001 |
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Follow-Up Studies; Humans; Middle Aged; Models, Theoretical; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Treatment Outcome | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53 | 2004 |
[Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life | 2004 |
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Perioperative Care; Platinum; Pneumonectomy; Survival Rate; Treatment Outcome | 2005 |
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate | 2005 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genes, Neoplasm; Humans; Inhibitory Concentration 50; Models, Biological; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Treatment Outcome | 2006 |
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Time Factors | 2006 |
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate | 2006 |
Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Platinum; Radiotherapy; Treatment Outcome | 2006 |
[The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Immunohistochemistry; Middle Aged; Ovarian Neoplasms; Ovary; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2007 |
Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytotoxins; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Platinum; Quality of Life; Treatment Outcome | 2007 |
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kinetics; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies | 2008 |
Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cesarean Section; Female; Humans; Hysterectomy; Magnetic Resonance Imaging; Neoadjuvant Therapy; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Cervical Neoplasms | 2010 |
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cystadenocarcinoma, Mucinous; Databases, Factual; Disease Progression; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Young Adult | 2010 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum | 2012 |
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 2012 |
Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
Topics: Animals; Antibodies; Antigens, Surface; Antineoplastic Agents, Phytogenic; Cell Growth Processes; Cell Line, Tumor; Contrast Media; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Mice; Mice, Nude; Micelles; Paclitaxel; Particle Size; Platinum; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Platinum; Premedication; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2012 |
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2013 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Gene Expression; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; tau Proteins; Treatment Outcome | 2013 |
[Comparison of platinum-containing doublet chemotherapy and liposome paclitaxel monotherapy for the treatment of elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liposomes; Lung Neoplasms; Male; Paclitaxel; Platinum; Treatment Outcome | 2013 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Choline; Choline Kinase; Down-Regulation; Doxorubicin; Female; Humans; Lipid Metabolism; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Platinum; RNA Interference; Signal Transduction; Transcriptome | 2014 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence | 2014 |
One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE).
Topics: Aged; Cardiovascular Diseases; Chromium; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Europe; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Percutaneous Coronary Intervention; Platinum; Product Surveillance, Postmarketing; Prospective Studies; Reoperation; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2015 |
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers | 2014 |
MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Neutrophils; Paclitaxel; Platinum; Vascular Endothelial Growth Factor A | 2015 |
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-kappa B; Paclitaxel; Platinum; Signal Transduction; Transcription Factor RelA; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Self-Assembly of Amphiphilic Drug-Dye Conjugates into Nanoparticles for Imaging and Chemotherapy.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Cell Survival; Coloring Agents; Coordination Complexes; Humans; MCF-7 Cells; Microscopy, Confocal; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Platinum; Spectrophotometry, Ultraviolet | 2016 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |
Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Topics: Adult; Aged; Anus Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Pyrimidines | 2017 |
Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cytoskeleton; DNA, Mitochondrial; Drug Resistance, Neoplasm; Female; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Tubulin | 2017 |
Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Mice; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms.
Topics: Animals; Antineoplastic Agents; Cell Dedifferentiation; Cell Shape; Cell Survival; Cells, Cultured; Cisplatin; Coculture Techniques; Galectin 3; Ganglia, Spinal; Mice; Mitochondria; Myelin Sheath; Neurons; Oxaliplatin; Paclitaxel; Platinum; Rats; Receptor, Nerve Growth Factor; Schwann Cells; Sciatic Nerve; Taxoids | 2017 |
Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2016 |
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2018 |
Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
Topics: Biomarkers; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum | 2018 |
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Topotecan | 2019 |
Clinical outcomes following implantation of the ION™ paclitaxel-eluting platinum chromium coronary stent in routine clinical practice: Results of the ION U.S. post-approval study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Platinum; Product Surveillance, Postmarketing; Prospective Studies; Prosthesis Design; Registries; Time Factors; Treatment Outcome; United States | 2019 |
Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Esophageal Neoplasms; Hospitals, Community; Humans; Irinotecan; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Metal-shell nanocapsules for the delivery of cancer drugs.
Topics: Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Delivery Systems; Emulsions; Humans; Metal Nanoparticles; Paclitaxel; Particle Size; Platinum; Surface Properties | 2020 |
Platelet-derived nanomotor coated balloon for atherosclerosis combination therapy.
Topics: Animals; Antibodies; Atherosclerosis; Cells, Cultured; Coated Materials, Biocompatible; Combined Modality Therapy; Diet, High-Fat; Humans; Mice; Nanoparticles; Paclitaxel; Particle Size; Phototherapy; Platinum; Porosity; Rabbits; RAW 264.7 Cells; Silicon Dioxide; Surface Properties | 2020 |
Chemo-Photothermal Combination Cancer Therapy with ROS Scavenging, Extracellular Matrix Depletion, and Tumor Immune Activation by Telmisartan and Diselenide-Paclitaxel Prodrug Loaded Nanoparticles.
Topics: Animals; Drug Delivery Systems; Glutathione; Humans; Metal Nanoparticles; Paclitaxel; Photothermal Therapy; Platinum; Prodrugs; Reactive Oxygen Species; Telmisartan; Transforming Growth Factor beta; Tumor Microenvironment | 2020 |
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Paclitaxel; Platinum; Tumor Microenvironment | 2020 |
Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer.
Topics: Albumins; Canada; Carcinoma, Transitional Cell; Humans; Paclitaxel; Platinum | 2021 |
Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer-Reply.
Topics: Albumins; Humans; Neoplasms; Paclitaxel; Platinum | 2021 |
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Rad51 Recombinase | 2021 |
Treatment-related leukemia after taxane and platinum therapy in gynecological cancer patients (Gynecologic Oncology Trial and Investigation Consortium 011).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Genital Neoplasms, Female; Humans; Leukemia; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Taxoids | 2021 |
Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Signal Transduction; Tumor Cells, Cultured | 2021 |
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum | 2021 |
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Uterine Cervical Neoplasms; Vulvar Neoplasms | 2022 |
IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Integrin alpha6; Mice; Neoplasm Metastasis; Paclitaxel; Platinum; Receptor, IGF Type 1; S100 Calcium-Binding Protein A4; Signal Transduction | 2022 |
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrazoles; Pyrimidinones | 2022 |
Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Female; Humans; Ifosfamide; Middle Aged; Paclitaxel; Platinum; Postoperative Period; Retrospective Studies; Uterine Neoplasms | 2022 |
Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies | 2022 |
Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies | 2023 |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Liver Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Thymoma; Thymus Neoplasms | 2022 |
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
Topics: Female; Humans; Ki-67 Antigen; Mesothelioma, Malignant; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies | 2022 |
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cost-Benefit Analysis; Delivery of Health Care; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Platinum; Quality-Adjusted Life Years; Trastuzumab | 2022 |
Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Transitional Cell; Cisplatin; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Paclitaxel; Phosphoglycerate Kinase; Platinum; Retrospective Studies | 2022 |
RGD peptide modified platinum nanozyme Co-loaded glutathione-responsive prodrug nanoparticles for enhanced chemo-photodynamic bladder cancer therapy.
Topics: Cell Line, Tumor; Glutathione; Humans; Nanoparticles; Oligopeptides; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Platinum; Polyethylene Glycols; Prodrugs; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Platinum; Prognosis | 2023 |
Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2023 |
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia | 2023 |
Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Paclitaxel; Pilot Projects; Platinum; Retrospective Studies; Uterine Cervical Neoplasms | 2023 |
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2023 |